* Innovative Medication Development & Enhancement Company.
* Patents for Extraction, Concentration & Processing of Specialized Medicinal Compounds.
* New Marketing to Mexico in Collaboration with Factoria Bogar Subsidiary.
* Balance Sheet Strengthened by $1.4 Million from June Warrant Exercise.
* New Oral Thin Film Products for High Value Male Dysfunction Market.
On June 3rd CURR, an innovative medication development and enhancement company, announced a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico. PMI will have access to the CURR bio-product platform, CUREform™ for its medication formulation, and become its distribution partner in Mexico for CURR wellness products, such as its vitamin D, sleep and specialized botanical extract products.
The CURR weekly vitamin D product provides 50,000 IU of vitamin D3 to reduce the risk of infections. CURR sleep strips contain a soothing blend of melatonin, naturally occurring amino acids and beneficial vitamins that promote fast-acting, balanced sleep patterns for a deep, restful slumber and a rejuvenated awakening.
The PMI collaboration will include several development initiatives with its proprietary prebiotic product from Agave in combination with special botanical extracts that leverage the CURR CUREform™ novel delivery platform for treatment of multiple GI indications. Patient studies are planned for Mexico to improve medication efficacy with CURR extracts and prebiotics.
On June 9th CURR announced it strengthened its balance sheet with the receipt of $1.4 million in cash from the exercise of warrants to purchase 708,467 shares of CURR common stock held by stockholders of Chemistry Holdings, Inc. at a reduced exercise price of $2.00 per share. The warrant exercise is part of the completion of all earn-out arrangements and obligations related to the CURR acquisition of Chemistry Holdings on May 14, 2019.
Additionally, on June 16th CURR named Jonathan Berlent, to the position of Chief Business Officer. Mr. Berlent will be responsible for corporate strategy, sourcing and executing business development opportunities and will serve as a member of the company’s Executive Management Committee. Mr. Berlent is an accomplished business growth executive with more than 25 years of private and public company experience focused on strategic partnerships and building businesses seeking to own end-to-end market verticals. He has led successful strategic business initiatives across the pharmaceutical, healthcare, life sciences and health & wellness industries, with particular focus on CBD and cannabis, as well as diseases of the central nervous system, or CNS.
* New Patents Issued on Key Therapeutics for Infectious Diseases
On April 21st CURR announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. The patents represent an expansion of the existing CURR “product by process” patents for obtaining multiple unique concentrates using super critical fluid extraction (SCFE). These include concentrates which have shown promising therapeutic activity in animal studies in areas such as inflammatory bowel disease, cancer and infectious diseases.
Additionally, CURR is granting equipment manufacturers, processing companies and medicine developers licenses to its portfolio of issued and pending process and composition patents for isolating specific botanical compounds using an advanced SCFE technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of extracts into multiple dosage forms, CURR has retained all rights to applying these methods in oral thin films.
The two new CURR patents cover the extraction and purification of specialized plant material, as well as subsequent processing of extracts for medication formulations. This extraction and fractioning of bioactive molecules allows for the integration of molecules into dosage forms.
* New Applications in the Multi-Billion Dollar Male Dysfunction Market
This news follows up on a CURR announcement of March 17th which detailed the allowance of Chinese Patent No. ZL201480039313.6 regarding the loading of high amounts of active medicine on an oral thin film using its proprietary delivery systems. This new patent includes the company’s lead product, CUREfilm Blue™, a soluble thin film for oral administration of sildenafil citrate to treat male dysfunction (ED) in China.
The ED market is expected to reach USD $6.5 billion at a 6% compound annual growth rate by 2025, according to QYResearch. The report points out that the Asia Pacific market will be one of the fastest growing markets for ED medicine. Sildenafil is leading the ED market worldwide with more than half of all global sales.
The CURR ED patent covers methods of preparing edible thin films that can deliver high doses of active ingredients that are encapsulated using lipids to form micelles or liposomes. This enables CURR to differentiate its oral thin film product from sildenafil oral soluble films.
For more Information visit the CURR company website at: https://www.curepharmaceutical.com/
Company Name: Cure Pharmaceuticals, Inc.
Contact Person: Media Relations
Email: Send Email
Phone: (805) 824-0410
Address:1620 Beacon Place
State: CA 93033
Country: United States